Quantum-Si To Present Poster on Single-Molecule Method for Detection of Arginine Post-Translational Modifications at the AACR Annual Meeting 2023

GUILFORD, Conn.–(BUSINESS WIRE)–#theproteinsequencingcompanyQuantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it will be presenting a poster on a new method for detection of arginine post-translational modifications (PTMs) using Platinum™, the world’s first next-generation single-molecule protein sequencing platform, at the American Association for Cancer Research’s (AACR) Annual Meeting 2023. The conference will take place April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.

Dr. Kenneth Skinner, a Staff Scientist at The Company, will present a poster titled: Detection of arginine post-translational modifications by single-molecule protein sequencing on the Quantum-Si Platinum Platform on Tuesday, April 18, from 1:30-5:00 p.m. The poster presentation can be found at poster section 29 and the presentation number is 5301.

The poster presentation will include a novel method for demonstrating the detection and differentiation of arginine PTMs. Current PTM detection approaches, such as mass spectrometry, can be challenging as they may be hampered by low abundance or mass differences. The results indicate single-molecule protein sequencing offers not only a viable technique for the detection of arginine PTMs, but a method that may outperform these current methods. The ability to directly detect arginine PTMs is vitally important for biomedical research, and points to potential future applications of Platinum in critical areas of cancer research such as biomarker development, PTM crosstalk, and drug discovery.

Platinum is the world’s first next-generation single-molecule protein sequencing platform. Quantum-Si’s single-molecule technology monitors amino-acid specific patterns in fluorescent probe behavior using a single probe. Its elegant simplicity enables broad-scale access to proteomic data, making it a critical instrument for the future of proteomics research. With its small 19.5-inch by 8.5-inch footprint benchtop design and low price-point of $70,000, Platinum is poised to accelerate breakthroughs across scientific disciplines, from drug discovery to biotech, and help people live healthier and longer lives.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com.

Forward Looking Statements This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; our ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report for the fiscal year ended December 31, 2022, and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contacts

Investor Contact
Juan Avendano

[email protected]

Media Contact
Michael Sullivan

[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.